Multimarker Quantitative Real-Time PCR Detection of Circulating Melanoma Cells in Peripheral Blood: Relation to Disease Stage in Melanoma Patients

Koyanagi, Kazuo; Kuo, Calvin; Nagao, Taku; Mori, Takuji; Ueno, Hideaki; Lorico, Arnulfo R.; Wang, He-Jing; Hseuh, E. J.; O’Day, Steven; Hoon, Dave S.B.

doi:10.1373/clinchem.2004.045096

Cited by 95 publications

(142 citation statements)

References 26 publications

Supporting

Mentioning

134

Contrasting

Unclassified

Order By: Relevance

“…The second step is the detection of CTC by immunocytochemical cell sorting or by highly sensitive molecular genetic methods such as RT-PCR (reverse transcription PCR) directed at tumor-specific mRNA. Interestingly, some authors have performed RT-PCR even without prior pre-concentration [10,27]. Aside from just detecting their presence, the molecular profile of CTC may serve as a predictor of treatment response and survival as demonstrated in several studies [11,12,[28][29][30].…”

mentioning

confidence: 99%

Monitoring of Circulating Tumor Cells by a Combination of Immunomagnetic Enrichment and RT-PCR in Colorectal Cancer Patients Undergoing Surgery

et al. 2016

View full text Add to dashboard Cite

Background. The presence of circulating tumor cells (CTC) has been reported in patients with advanced colorectal cancer. Monitoring CTC (also known as a liquid-biopsy) has recently become the center of interest for low-invasive monitoring of cancer progression and predictive biomarkers testing. Along with high-cost technology and a complex methodology, a straightforward method based on magnetic beads enrichment followed by RT-PCR is set to allow for routine CTC analysis in colorectal cancer patients. Objectives. The main purpose of this study was to evaluate the possibility of CTC detection in routine monitoring of patients starting before and continuing after surgery. Material and Methods. The investigated group consisted of 30 patients mainly in advanced stages of colorectal cancer. In all patients, CTC detection was performed prior to surgery, in a subset of 14 patients additional sampling was done during and after surgery. In all cases, peripheral blood was processed using AdnaTest ColonCancer kit, which relies on enriching CTCs using EpCAM-functionalized magnetic beads and subsequently identifying tumorspecific CEA, EGFR and GA733-2 mRNA transcripts. Results. Out of all the tested samples, CTC were found in one patient suffering from advanced disease with lung and liver metastases. There, however, the positive finding was confirmed in 3 consecutive samples acquired before, during and shortly after palliative R2 resection. Conclusions. The presence of CTC may be used to observe post-operative disease development. Due to the overall low CTC detection, further technology development may be necessary before its universal applicability to manage colorectal cancer patients (Adv Clin Exp Med 2016, 25, 6, 1273-1279).

show abstract

mentioning

confidence: 99%

Monitoring of Circulating Tumor Cells by a Combination of Immunomagnetic Enrichment and RT-PCR in Colorectal Cancer Patients Undergoing Surgery

et al. 2016

View full text Add to dashboard Cite

show abstract

“…29 In our study we concentrated on 5 melanoma markers: Melan-A/MART-1, gp 100, MAGE-3, MIA a tyrosinase. MAGE-3 was identified as the most sensitive progression marker (elevation in 17 out of 18 patients), followed by gp 100 (10 out of 18), MIA (9 out of 18) and tyrosinase with 1 elevation.…”

Section: Discussionmentioning

confidence: 99%

Early Detection of Melanoma Progression by Quantitative Real-time RT-PCR Analysis for Multiple Melanoma Markers

2008

View full text Add to dashboard Cite

Standard screening of melanoma patients is a useful tool for predicting outcome of patients, however, an instant methodology for exact detection of subclinical disease or monitoring treatment response is under investigation.Detection of circulating melanoma cells is, therefore, a possible novel promising staging method. However, inconsistent data on method sensitivity and on the predicted patient outcome has been shown repeatedly.Recently, a multimarker real-time RT-PCR methodology for quantification of five melanoma markers Melan-A, gp 100, MAGE-3, MIA and tyrosinase was described by our group. In the current prospective trial, blood specimens of 65 patients with AJCC stage IIB-III cutaneous melanoma after surgery were periodically examined. In the above group, 27 % of subjects relapsed during the study. Prior to the disease progression we could observe a statistically significant tumor marker elevation in previous 0 to 9 months in all patients with clinical relapse. MAGE-3 became the most sensitive progression marker. During progression, three concordant positive markers were seen in 39 % of patients, followed by two concordant positive markers in 28 % and 1 marker in 33 %.This study supports the use of a multimarker real-time RT-PCR as a disease progression predictor. The dynamic assessment of serially obtained blood specimens represents a useful method for early metastasis detection and treatment response of melanoma patients. (Keio J Med 57 (1) : 57 -64, March 2008)

show abstract

“…CTPs can have high sensitivity for early-stage disease, and studies have successfully described the ability to detect ctDNA or mRNA in early-stage melanoma and other cancers [44,53]. The implications are enormous, as many cancers such as ovarian and pancreatic carcinomas tend to present clinically in later stages and may serve to benefit the most from early detection.…”

Section: Screeningmentioning

confidence: 99%

“…However, no studies have yet investigated CTCs in melanoma diagnosis. While circulating mRNA can be found in patients with early-stage disease [53], the potential of mRNA or ctDNA as a diagnostic tool seems limited because of the incompatibility of this technology with commonly used methods for melanoma cancer diagnosis.…”

Section: Diagnosticsmentioning

confidence: 99%

“…Another important application of CTPs as prognostic biomarkers lies in the correlation between CTPs and traditional prognosticators such as stage and disease volume [22,[53][54][55]. Of particular use to clinical melanoma management isthe ability to further risk stratify patients with stage II (sentinel lymph node negative) disease into groups of low and high risk for recurrence.…”

Section: Ctps As Prognostic Biomarkersmentioning

confidence: 99%

See 1 more Smart Citation

Circulating Tumor Cells, DNA, and mRNA: Potential for Clinical Utility in Patients With Melanoma

Dorsey

Amaravadi

et al. 2015

The Oncologist

View full text Add to dashboard Cite

Circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and messenger RNA (mRNA), collectively termed circulating tumor products (CTPs), represent areas of immense interest from scientists' and clinicians' perspectives. In melanoma, CTP analysis may have clinical utility in many areas, from screening and diagnosis to clinical decisionmaking aids, as surveillance biomarkers or sources of realtime genetic or molecular characterization. In addition, CTP analysis can be useful in the discovery of new biomarkers, patterns of treatment resistance, and mechanisms of metastasis development. Here, we compare and contrast CTCs, ctDNA, and mRNA, review the extent of translational evidence to date, and discuss how future studies involving both scientists and clinicians can help to further develop this tool for the benefit of melanoma patients. The Oncologist 2016;21:84-94 Implications for Practice: Scientific advancement has enabled the rapid development of tools to analyze circulating tumor cells, tumor DNA, and messenger RNA, collectively termed circulating tumor products (CTPs). A variety of techniques have emerged to detect and characterize melanoma CTPs; however, only a fraction has been applied to human subjects.This review summarizes the available human data that investigate clinical utility of CTP in cancer screening, melanoma diagnosis, prognosis, prediction, and genetic or molecular characterization. It provides a rationale for how CTPs may be useful for future research and discusses how clinicians can be involved in developing this exciting new technology.

show abstract

Multimarker Quantitative Real-Time PCR Detection of Circulating Melanoma Cells in Peripheral Blood: Relation to Disease Stage in Melanoma Patients

Cited by 95 publications

References 26 publications

Monitoring of Circulating Tumor Cells by a Combination of Immunomagnetic Enrichment and RT-PCR in Colorectal Cancer Patients Undergoing Surgery

Monitoring of Circulating Tumor Cells by a Combination of Immunomagnetic Enrichment and RT-PCR in Colorectal Cancer Patients Undergoing Surgery

Early Detection of Melanoma Progression by Quantitative Real-time RT-PCR Analysis for Multiple Melanoma Markers

Circulating Tumor Cells, DNA, and mRNA: Potential for Clinical Utility in Patients With Melanoma

Contact Info

Product

Resources

About